Selumetinib
- Generic Name
- Selumetinib
- Brand Names
- Koselugo
- Drug Type
- Small Molecule
- Chemical Formula
- C17H15BrClFN4O3
- CAS Number
- 606143-52-6
- Unique Ingredient Identifier
- 6UH91I579U
- Background
Activation of the Raf-MEK-ERK signaling pathway is known to be implemented in several types of malignancies, thus, mitogen-activated protein kinase kinase (MEK) inhibitors such as selumetinib are important tools that can target the problematic overactivity of this pathway.
...
- Indication
Although selumetinib has been investigated for the treatment of several types of cancer, it is currently only indicated for the treatment of neurofibromatosis type 1 (NF1) in patients ≥2 years who have symptomatic, inoperable plexiform neurofibromas (PN).
- Associated Conditions
- Neurofibromatosis, type 1 (von Recklinghausen's disease)
- Associated Therapies
- -
To Assess the Effects of Single Oral Dose of Selumetinib [AZD6244; ARRY-142886] [Hyd-Sulfate]), on QTc Interval in Healthy Male Volunteers
- Conditions
- Interventions
- First Posted Date
- 2014-02-06
- Last Posted Date
- 2015-11-09
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 54
- Registration Number
- NCT02056392
- Locations
- 🇺🇸
Research Site, Overland Park, Kansas, United States
To Assess the Effect of Rifampicin on the Pharmacokinetics of Selumetinib in Healthy Male Volunteers
- First Posted Date
- 2014-01-28
- Last Posted Date
- 2014-04-29
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 24
- Registration Number
- NCT02046850
- Locations
- 🇺🇸
Research Site, Overland Park, Kansas, United States
Selumetinib in Combination With Gefitinib in NSCLC Patients
- First Posted Date
- 2013-12-31
- Last Posted Date
- 2018-07-10
- Lead Sponsor
- National Taiwan University Hospital
- Target Recruit Count
- 34
- Registration Number
- NCT02025114
- Locations
- 🇨🇳
National Cheng Kung University Hospital, Tainan, Taiwan
🇨🇳Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan
🇨🇳Taipei Veterans General Hospital, Taipei, Taiwan
Dose-escalation Study to Assess Selumetinib Safety, Tolerability and PK
- First Posted Date
- 2013-10-10
- Last Posted Date
- 2014-06-02
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 117
- Registration Number
- NCT01960374
- Locations
- 🇬🇧
Research Site, London, United Kingdom
Selumetinib (AZD6244, ARRY-142886) J-BTC Phase 1 Study
- Conditions
- Interventions
- First Posted Date
- 2013-09-25
- Last Posted Date
- 2016-05-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 6
- Registration Number
- NCT01949870
- Locations
- 🇯🇵
AZD6244 PhI Japanese Gem/, Chuo Ku, Tokyo, Japan
Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Positive NSCLC
- Conditions
- Interventions
- First Posted Date
- 2013-09-02
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 510
- Registration Number
- NCT01933932
- Locations
- 🇬🇧
Research Site, Wolverhampton, United Kingdom
Selumetinib and Akt Inhibitor MK-2206 in Treating Patients With Refractory or Advanced Gallbladder or Bile Duct Cancer That Cannot Be Removed By Surgery
- Conditions
- Recurrent Adult Primary Liver CancerAdenocarcinoma of the GallbladderAdult Primary Cholangiocellular CarcinomaStage II Gallbladder CancerStage IIIB Gallbladder CancerStage IVA Gallbladder CancerCholangiocarcinoma of the Extrahepatic Bile DuctRecurrent Extrahepatic Bile Duct CancerStage IIIA Gallbladder CancerStage IVB Gallbladder Cancer
- Interventions
- First Posted Date
- 2013-05-21
- Last Posted Date
- 2014-09-09
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT01859182
Comparing Complete Remission After Treatment With Selumetinib/Placebo in Patient With Differentiated Thyroid Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-04-30
- Last Posted Date
- 2019-08-28
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 233
- Registration Number
- NCT01843062
- Locations
- 🇸🇪
Research Site, Stockholm, Sweden
Assess Safety & Efficacy of Selumetinib When Given in Combination With Standard First Line Treatment for Advanced Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2013-03-12
- Last Posted Date
- 2018-03-13
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 55
- Registration Number
- NCT01809210
- Locations
- 🇬🇧
Research Site, Newcastle upon Tyne, United Kingdom
Study of Selumetinib in Patients With Previously Treated or Untreated Advanced/Metastatic NSCLC
- Conditions
- Interventions
- First Posted Date
- 2013-02-04
- Last Posted Date
- 2023-08-04
- Lead Sponsor
- Canadian Cancer Trials Group
- Target Recruit Count
- 39
- Registration Number
- NCT01783197
- Locations
- 🇨🇦
BCCA - Vancouver Cancer Centre, Vancouver, British Columbia, Canada
🇨🇦Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, Ontario, Canada
🇨🇦Ottawa Hospital Research Institute, Ottawa, Ontario, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.